How to Treat Gout in the Knee and Prevent Flares

Treating gout in the knee means tackling two separate problems: shutting down the acute flare that has your knee swollen, hot, and excruciating, and then lowering your uric acid over months so flares stop coming back. Most people focus on the first part because the pain demands it, but lasting relief depends almost entirely on the second. The knee is one of the larger joints gout targets, and its size can make flares especially debilitating because you need that joint to walk, climb stairs, and get out of a chair.

Why Gout Hits the Knee Hard

Gout develops when uric acid in the blood climbs high enough for needle-shaped crystals of monosodium urate (MSU) to form inside a joint. Once those crystals land on cartilage or surrounding tissue, the immune system treats them as a danger signal and launches an intense inflammatory cascade driven by a protein complex called the NLRP3 inflammasome, which floods the joint with the inflammatory messenger IL-1β.¹ That process is the same regardless of which joint is affected, but the knee has a large synovial cavity, which means there is more tissue surface for crystals to accumulate on and more room for inflammatory fluid to pool. The result is a massively swollen, stiff knee that can make bearing weight nearly impossible.

Most people associate gout with the big toe, and that is where a first attack often strikes. But repeat flares frequently move to mid-foot joints, ankles, and knees. A knee flare can be mistaken for a torn meniscus, an infected joint, or a rheumatoid arthritis flare, so accurate diagnosis matters before you settle on a treatment plan.

Getting the Diagnosis Right

Joint fluid analysis remains the gold-standard test. A doctor draws fluid from the swollen knee with a needle and examines it under polarized light microscopy. If MSU crystals are present, the diagnosis is confirmed. This step also rules out septic arthritis, which is a joint infection that can look almost identical to a gout flare but requires antibiotics rather than anti-inflammatory therapy. Skipping the fluid draw and guessing based on symptoms alone is risky, especially for a first knee episode.

Imaging can help when a fluid draw is not feasible or when the clinical picture is ambiguous. Ultrasound can pick up a characteristic “double contour sign,” a bright line over the cartilage surface caused by urate crystal deposits. One study found that sign in over 90% of gouty joints and in none of the controls.² Dual-energy computed tomography (DECT) is another option that can highlight urate deposits throughout the body, though ultrasound tends to be used first because it is cheaper, radiation-free, and at least as sensitive in the knee.³

Treating an Acute Knee Flare

When a gout flare hits the knee, speed matters. The earlier you start treatment, the faster the pain resolves. Three categories of medication are considered first-line for acute flares, and the choice depends on your other health conditions, medications you are already taking, and how many joints are involved.

Colchicine

Colchicine works best when taken within the first 12 to 24 hours of a flare. Current guidelines recommend a loading dose of 1 mg followed by 0.5 mg one hour later, then 0.5 mg two to three times daily over the following days.⁴ Diarrhea is the most common side effect and also the earliest warning of colchicine toxicity, so you should reduce the dose if it appears. People with kidney disease or those taking certain medications that affect how colchicine is processed need a lower dose from the start. The drug is less helpful once a flare has been raging for a couple of days, so timing is everything.

NSAIDs

Non-steroidal anti-inflammatory drugs like indomethacin and naproxen are a common alternative, especially for people who tolerate them well. A network meta-analysis across 30 randomized trials found that indomethacin-type NSAIDs improved joint swelling more than ibuprofen-class NSAIDs and also scored better on patients’ overall assessment of their condition.⁵ However, NSAIDs carry risks for the stomach, kidneys, and cardiovascular system, and they are generally best avoided in older adults, people with kidney problems, and anyone on blood thinners.⁶

Corticosteroids

For the knee specifically, a corticosteroid injection directly into the joint is an appealing option because it delivers high-dose anti-inflammatory medication right where you need it while minimizing whole-body side effects. Injecting corticosteroids into arthritic joints has been standard practice for decades, and for an accessible large joint like the knee the technique is straightforward.⁷ In older adults, intra-articular injection is often the preferred first-line treatment for knee gout.⁶ That said, a Cochrane review noted that randomized trial evidence specifically supporting intra-articular steroids for acute gout is surprisingly thin, even though clinicians use the technique routinely and report good results.⁸ When injection is not practical or if multiple joints are involved, oral prednisolone is a solid alternative.

When First-Line Treatments Fail

Some people cannot use any of the standard three options because of kidney disease, drug interactions, or side effects. IL-1 inhibitors such as canakinumab and anakinra target the inflammatory messenger at the core of the gout flare. In network meta-analysis, canakinumab provided the greatest pain reduction at two days compared with other treatments.⁵ However, these drugs are expensive and carry infection risks, so current guidelines reserve them for cases where colchicine, NSAIDs, and corticosteroids are all ineffective, poorly tolerated, or off the table.⁹

Lowering Uric Acid to Prevent Future Flares

Treating individual flares is necessary but not sufficient. Without addressing the underlying problem of high uric acid, crystals continue to deposit in the joint and flares keep returning, potentially getting more frequent and more severe over time. Urate-lowering therapy (ULT) is the backbone of long-term gout management, and the goal is to bring serum uric acid below a target level, typically under 6 mg/dL, so existing crystals gradually dissolve and new ones stop forming.

Allopurinol is the most widely prescribed ULT worldwide. It works by blocking the enzyme xanthine oxidase, which is responsible for converting purines into uric acid. Doctors usually start it at a low dose and increase gradually, a “start low, go slow” strategy that reduces the risk of triggering a paradoxical gout flare during the early weeks of treatment. A rare but serious skin reaction called allopurinol hypersensitivity syndrome is linked to a genetic marker, HLA-B*58:01. In a large prospective study in Taiwan, screening patients for the marker and withholding allopurinol from carriers completely prevented severe cutaneous reactions, whereas seven cases would have been expected based on historical rates.¹⁰ The prevalence of this marker varies by ethnicity, and screening is recommended before starting allopurinol in populations where the marker is more common, particularly people of Southeast Asian, Korean, or African American descent.

Febuxostat is another xanthine oxidase inhibitor that can achieve greater uric acid lowering than allopurinol in some patients.¹¹ It is often used when allopurinol is not tolerated or does not bring uric acid to target. For people with severe, treatment-resistant gout who have failed conventional ULT, pegloticase is an option. This is an enzyme infusion that directly breaks down uric acid in the blood, profoundly lowering levels, shrinking tophi, reducing tender and swollen joint counts, and improving quality of life.¹² It is reserved for refractory cases because it requires intravenous infusion and carries a risk of infusion reactions.

The Tricky First Months of Urate-Lowering Therapy

One of the most frustrating aspects of starting ULT is that you can actually get more flares before you get fewer. When uric acid levels drop rapidly, crystals that have been sitting in your joint begin to shift and dissolve, and that movement can trigger the same inflammatory response as crystal deposition. This does not mean the treatment is failing. It means things are changing inside the joint, and your immune system is reacting to it.

To get through this transition, many doctors prescribe low-dose colchicine alongside the new ULT for the first three to six months. A randomized trial showed that patients receiving colchicine prophylaxis during allopurinol initiation experienced far fewer flares than those who did not, averaging about half a flare over six months compared with nearly three flares in the group without prophylaxis.¹³ A more recent trial tested whether the start-low-go-slow allopurinol strategy alone could make colchicine prophylaxis unnecessary. It could not: the group without colchicine still had significantly more flares.¹⁴ The takeaway is that even with a cautious dose-escalation approach, prophylactic anti-inflammatory coverage during the first months of ULT is still worth using.

Why So Many People Stop Treatment Too Soon

Adherence to urate-lowering therapy is notoriously poor. Unlike blood pressure medication, where you never feel a direct benefit, gout medication offers a very clear promise: no more agonizing flares. Yet studies consistently show that a large share of patients stop taking their ULT or take it inconsistently.¹⁵ Common barriers include doubts about whether the medication really works, worries about cost and side effects, having too many other medications to keep track of, difficulty swallowing large pills, and a preference for trying cherry juice or other home remedies instead.¹⁶

The early-flare paradox described above may also contribute. If you start a medication that is supposed to prevent gout and then you get hit with a flare worse than any you have had, it is natural to conclude the drug is making things worse and toss the bottle. Understanding in advance that early flares are a known, temporary side effect of urate lowering can help you stick with the plan. Regular uric acid monitoring and follow-up visits reinforce that the drug is doing its job by showing your levels dropping over time.

Diet, Hydration, and Weight

If you search for gout advice online, you will find long lists of foods to avoid, from organ meats to shellfish to beer. There is truth behind some of it, but the overall effect of diet on uric acid levels is modest. A review of the evidence concluded that dietary factors have a small effect on serum urate and that their impact on the long-term course of gout is uncertain. Urate-lowering medication remains the mainstay of treatment, with diet playing a limited supporting role.¹⁷

That does not mean lifestyle changes are useless. Losing weight, if you carry extra, can meaningfully reduce uric acid and flare frequency. A pilot study of gout patients who lost weight through moderate calorie restriction saw their average monthly attacks drop from about two to less than one, and uric acid levels normalized in more than half of participants whose levels had been elevated.¹⁸ The important caveat: crash dieting, fasting, and intense exercise can actually raise uric acid in the short term and provoke a flare.¹⁹ Gradual weight loss and regular moderate activity are the safer route. Staying well hydrated also helps the kidneys clear uric acid more efficiently.

Alcohol, especially beer, is worth cutting back on because it raises uric acid both by increasing production and decreasing excretion. Sugary drinks sweetened with fructose have a similar effect. Neither elimination will replace ULT, but both can reduce the frequency of breakthroughs.

What Happens If Knee Gout Goes Untreated

Repeated flares in the knee without urate lowering can cause lasting structural damage. MRI studies show that cartilage damage in gouty joints correlates with the size of tophaceous deposits (the chalky lumps of crystallized urate that build up over years) and with the degree of bone erosion and synovitis in the joint.²⁰ In the knee, advanced tophaceous gout can restrict range of motion, cause chronic pain, and eventually require surgical intervention. One case report documented arthroscopic removal of intra-articular tophi from a knee, with the patient recovering full function about six weeks after surgery, underscoring both that the damage is real and that aggressive treatment can still help even at a late stage.²¹

Beyond joint destruction, poorly managed gout is tied to broader health problems. As many as one-third of people with chronic kidney disease have a history of gout, and fewer than a quarter of them are effectively treated to target uric acid levels.²² The relationship goes both ways: kidney disease makes it harder to excrete uric acid, and persistently high uric acid and the systemic inflammation that comes with it are associated with increased cardiovascular risk.²³ Managing gout in patients who also have kidney disease is particularly complex because some medications are restricted or need dose adjustments, contributing to the undertreatment problem.

The Stigma Problem

Gout has a reputation as a disease of overindulgence, a caricature inherited from centuries of associating it with rich food and port wine. That stigma persists and has real consequences. In qualitative research, gout patients described anger at having their condition dismissed by friends, family, and even healthcare workers who did not take their pain seriously.²⁴ In a separate study, about a quarter of gout patients reported experiencing internalized stigma, and a similar proportion expected to be stigmatized by those around them. Younger patients, those with more severe pain, and those with greater illness-related disability were more likely to feel stigmatized, and increased stigma was associated with intentionally skipping urate-lowering medication.²⁵

This matters practically because stigma feeds non-adherence. If you feel embarrassed about having gout, you are less likely to fill prescriptions, attend follow-up appointments, or talk openly with your doctor about how well treatment is working. Some patients attribute their symptoms to normal aging aches rather than acknowledging the diagnosis, which delays effective treatment.²⁴ Gout is a metabolic condition driven primarily by how your body produces and excretes uric acid. Lifestyle factors can contribute at the margins, but the core problem is biochemical, not moral. Framing it that way, both to yourself and to skeptical people around you, can help you stay engaged with the treatment that actually prevents flares.

Keeping the Knee Functional Between Flares

Once an acute flare in the knee subsides, there is often lingering stiffness and weakness from days or weeks of guarding the joint. Gentle range-of-motion exercises, progressing to strengthening work for the quadriceps and hamstrings, help restore normal function. Swimming, cycling, and walking on flat surfaces are good choices because they build strength and endurance without heavy impact on the knee. The key is to keep moving without overdoing it, since very intense exercise can temporarily spike uric acid and trigger another episode.¹⁹

If you have had multiple flares in the same knee and notice that your range of motion is not fully returning, imaging can help determine whether tophi or early erosive changes are present. Catching structural damage early gives you and your doctor more options, whether that means intensifying ULT, switching to a different urate-lowering agent, or in rare cases considering arthroscopic debridement to remove tophaceous material from inside the joint.

1
PubMed Central. The Mechanism of the NLRP3 Inflammasome Activation and Pathogenic Implication in the Pathogenesis of Gout
2
Rheumatology. Diagnosis of gout by ultrasound
3
PubMed Central. Detection of uric acid crystal deposition by ultrasonography and dual-energy computed tomography
4
PubMed. 2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares
5
PubMed Central. Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Meta-Analysis
6
PubMed. Managing Gout Flares in the Elderly: Practical Considerations
7
PubMed. Injectable corticosteroids in treatment of arthritis of the knee
8
PubMed Central. Intra‐articular glucocorticoids for acute gout
9
PubMed Central. Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review
10
The BMJ. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study
11
PubMed Central. Febuxostat (Uloric), A New Treatment Option for Gout
12
PubMed. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety
13
PubMed. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis
14
Annals of the Rheumatic Diseases. Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial
15
PubMed Central. Treatment approaches and adherence to urate-lowering therapy for patients with gout
16
PubMed Central. Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
17
PubMed Central. Role of diet in hyperuricemia and gout
18
Annals of the Rheumatic Diseases. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study
19
PubMed Central. Nonpharmacological Management of Gout and Hyperuricemia: Hints for Better Lifestyle
20
PubMed. Exploring cartilage damage in gout using 3-T MRI: distribution and associations with joint inflammation and tophus deposition
21
PubMed Central. Arthroscopic Management of Intra-articular Tophaceous Gout of the Knee: A Case Report and Review of the Literature
22
PubMed. Controversies and practical management of patients with gout and chronic kidney disease
23
PubMed. Hyperuricemia – more than gout: Impact on cardiovascular risk and renal insufficiency
24
PubMed Central. “You want to get on with the rest of your life”: a qualitative study of health-related quality of life in gout
25
PubMed Central. Internalized and Anticipated Stigmatization in Patients With Gout